NCT02020590View on ClinicalTrials.gov

Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

January 30, 2020

Conditions
Long Bone Delayed-Union Fracture
Interventions
DRUG

ALLOB® implantation

Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.

Sponsors
All Listed Sponsors
lead

Bone Therapeutics S.A

INDUSTRY

NCT02020590 - Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures | Biotech Hunter | Biotech Hunter